Private equity firm Columbus Venture Partners and Cleon Capital led a €15m round in Cocoon Bioscience, a biotechnology company, with participation from Viscofan, North South Ventures, Sangha Capital and BASQUE. “The experience and support from the investors participating in this round will play a critical role as we grow Cocoon’s business over the coming months and years. Cocoon’s platform and the products manufactured have been successfully proven and pressure-tested many times over. Now, this round of funding will allow us to rapidly scale our platform to the industrial level so that we can address the exponential demand for high performance growth factor proteins for the cultivated meat industry as well as the need for cost-competitive enzymes involved in key healthcare applications such as mRNA and genetic sequencing," Josh Robinson, Cocoon CEO.